Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Interesting lead in the treatment of Ewing`s sarcoma

01.11.2002


Research scientists at INSERM, CNRS and the Institut Curie, in collaboration with physicians, have used a mouse model to demonstrate the efficacy of an innovative therapeutic approach to Ewing`s sarcoma: the combination of human interferon (alpha or beta) and a common anti-tumor agent, ifosfamide.



Their results were published in the November 2002 issue of Oncogene and point to an interesting lead in the development of a less intensive and more effective therapeutic strategy for Ewing`s sarcoma, a severe bone cancer occurring children and adolescents. Before holding out hope, particularly to patients with metastatic disease, whose survival rate is poor, these findings must be confirmed in clinical trials.

For several years now, Jeanne Wietzerbin and her team at the Institut Curie1 have been studying how interferons and other cytokines act on Ewing`s sarcoma. In this new study in mice, they have evaluated the anti-tumor efficacy of interferon-alpha and interferon-beta, two type I interferons, and the combination of one or other of these interferons with ifosfamide (IFO), a widely used anti-cancer agent.


Previous in vitro experiments had demonstrated the antiproliferative activity of these interferons on cell lines derived from Ewing`s sarcoma.

The next logical step was therefore to observe the in vivo activity of the interferons in so-called nude mice (immunodepressed), a relevant animal model of the disease. Ewing sarcoma cells were injected subcutaneously into the nude mice. As the mice are immunodepressed, the cells engraft and engender a solid tumor of human origin which can be used to evaluate the therapeutic potential of innovative treatments.

The administration of interferon-alpha or interferon-beta after injection of the tumor cells impaired engrafting and tumor growth. In addition, interferon-beta, and to a lesser extent interferon-alpha, delayed the growth of established tumors.

Promising synergy

Using this experimental model, the researchers also evaluated the activity of ifosfamide, which blocks DNA replication and hence cell proliferation. It was recently reported that ifosfamide, in conjunction with the chemotherapy conventionally used to treat Ewing`s sarcoma, improves the response in patients hitherto resistant to these treatments.
Jeanne Wietzerbin`s team has therefore pursued its approach in a series of experiments designed to assess the consequences of using interferon-alpha or interferon-beta combined with ifosfamide.

The results in the mouse are convincing. There was marked synergy between the interferon used and the chemotherapeutic agent, resulting in extended survival of the tumor-bearing animals: the necrosis of the tumor tissue was clearly greater than when interferon or ifosfamide was used alone. There was practically no tumor cell division, and the tumor tissue became fibrous and calcified.

It seems that the interferons sensitized the tumor cells to chemotherapy and that ifosfamide sensitized them to the antiproliferative effects of the interferons.

These observations are highly encouraging, especially as survival is poor in the advanced stages of the disease, or when the disease is metastatic at the time of diagnosis, despite intensive treatments combining surgery, chemotherapy and/or radiotherapy. Confirmation of these findings in clinical trials is now needed. The idea is to develop a new therapeutic strategy combining solely interferon and ifosfamide, to be used initially in patients resistant to conventional treatments.

Notes:

1 Jeanne Wietzerbin, director of research at CNRS, heads INSERM Unit 365 "Interferons and cytokines" at the Institut Curie

Reference

"Strong inhibition of Ewing’s sarcoma xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide"
Josiane Sancéau1, Marie-France Poupon2, Olivier Delattre3, Xavier Sastre-Garau4 and Juana Wietzerbin1
Oncogene, vol. 21, pp.7700-09, 31 October 2002

1INSERM U365, Institut Curie, 2CNRS-UMR 147, Institut Curie, 3INSERM U509, Institut Curie, 4Département de Pathologie, Institut Curie, Section Médicale

Press contacts

Institut Curie
Press Relations
Catherine Goupillon
Phone 33(0)1 44 32 40 63
service.presse@curie.fr

Iconography
Cécile Charré
Phone 33(0)1 44 32 40 51
Fax 33(0)1 44 32 41 67

Inserm
Press Office
Céline Goupil
Phone 33(0)1 44 23 60 73
presse@tolbiac.inserm.fr

Séverine Ciancia
Phone 33(0)1 44 23 60 86

CNRS
Press Office
Martine Hasler
Phone 33(0)1 44 96 46 35
martine.hasler@cnrs-dir.fr
Fax 33(0)1 44 96 49 93

Catherine Goupillon | Institut Curie

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Quantum thermometer or optical refrigerator?

23.06.2017 | Physics and Astronomy

A 100-year-old physics problem has been solved at EPFL

23.06.2017 | Physics and Astronomy

Equipping form with function

23.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>